The effect of obesity pharmacotherapy on body composition, including muscle mass

被引:2
作者
Argyrakopoulou, Georgia [1 ]
Gitsi, Evdoxia [1 ]
Konstantinidou, Sofia K. [1 ,2 ]
Kokkinos, Alexander [2 ]
机构
[1] Athens Med Ctr, Diabet & Obes Unit, Athens 15125, Greece
[2] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Dept Propaedeut Internal Med 1, Athens, Greece
关键词
BROWN ADIPOSE-TISSUE; WEIGHT-LOSS; DOUBLE-BLIND; LIRAGLUTIDE; SEMAGLUTIDE; STRENGTH; GLP-1; TRIAL; MG; OVERWEIGHT;
D O I
10.1038/s41366-024-01533-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 70 条
[61]   Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study (vol 37, pg 1443, 2013) [J].
Wadden, T. A. ;
Hollander, P. ;
Klein, S. ;
Niswender, K. ;
Woo, V. ;
Hale, P. M. ;
Aronne, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2015, 39 (01) :187-187
[62]   Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial [J].
Wadden, Thomas A. ;
Chao, Ariana M. ;
Machineni, Sriram ;
Kushner, Robert ;
Ard, Jamy ;
Srivastava, Gitanjali ;
Halpern, Bruno ;
Zhang, Shuyu ;
Chen, Jiaxun ;
Bunck, Mathijs C. ;
Ahmad, Nadia N. ;
Forrester, Tammy .
NATURE MEDICINE, 2023, 29 (11) :2909-2918
[63]   Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial [J].
Wadden, Thomas A. ;
Foreyt, John P. ;
Foster, Gary D. ;
Hill, James O. ;
Klein, Samuel ;
O'Neil, Patrick M. ;
Perri, Michael G. ;
Pi-Sunyer, F. Xavier ;
Rock, Cheryl L. ;
Erickson, Janelle S. ;
Maier, Holly N. ;
Kim, Dennis D. ;
Dunayevich, Eduardo .
OBESITY, 2011, 19 (01) :110-120
[64]   Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity [J].
Weiss, Edward P. ;
Jordan, Richard C. ;
Frese, Ethel M. ;
Albert, Stewart G. ;
Villareal, Dennis T. .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2017, 49 (01) :206-217
[65]  
Wilding J, 2021, study, V5, pA16
[66]   Once-Weekly Semaglutide in Adults with Overweight or Obesity [J].
Wilding, John P. H. ;
Batterham, Rachel L. ;
Calanna, Salvatore ;
Davies, Melanie ;
Van Gaal, Luc F. ;
Lingvay, Ildiko ;
McGowan, Barbara M. ;
Rosenstock, Julio ;
Tran, Marie T. D. ;
Wadden, Thomas A. ;
Wharton, Sean ;
Yokote, Koutaro ;
Zeuthen, Niels ;
Kushner, Robert F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11) :989-1002
[67]  
WOA, 2022, One billion people globally estimated to be living with obesity by 2030
[68]  
Xiang J, 2023, EUR REV MED PHARMACO, V27, P9908, DOI 10.26355/eurrev_202310_34169
[69]   GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway [J].
Xiang, Jie ;
Qin, Liyan ;
Zhong, Jinling ;
Xia, Ning ;
Liang, Yuzhen .
DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 :2433-2446
[70]   Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study [J].
Yu, Dongni ;
Zou, Mingzhu ;
Pan, Qi ;
Song, Yan ;
Li, Miao ;
Zhang, Xianbo ;
Zhou, Yan ;
Wang, Xiaoxia ;
Guo, Lixin .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13